^
Association details:
Biomarker:SMARCA4 mutation
Cancer:Lung Cancer
Drug:AU-19820 (SMARCA2 degrader)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

1144 - Orally bioavailable SMARCA2 degraders with exceptional selectivity and potency

Published date:
03/10/2021
Excerpt:
AU-19820 demonstrated potent anti-proliferative activity in SMARCA4 mutant but not in SMARCA2/4 proficient cell lines. Additionally, the lead compound exhibited significant tumor growth inhibition in RERF-LC-A1 (SMARCA4 mutant lung cancer)…